📬 GU Oncology Intelligence Digest — Week 2026-W29

FDA approved perioperative EV plus pembrolizumab for all cystectomy-eligible MIBC regardless of cisplatin eligibility, while JCOG1403 established single-dose intravesical pirarubicin after nephroureterectomy and a phase III trial showed adjuvant pelvic IMRT improves locoregional control in high-risk MIBC.

⚡ TL;DR

📄 Publications

Single, early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial. — 3-year relapse-free survival was 60.0% with pirarubicin vs 47.0% with observation (HR 0.67; p=0.0066)

🐦 Twitter / 🦋 Bluesky

FDA approves perioperative enfortumab vedotin plus pembrolizumab for all cystectomy-eligible MIBC (KEYNOTE-B15/EV-304) — KEYNOTE-B15/EV-304 showed 47% reduction in risk of recurrence, progression, or death (EFS HR 0.53) and 35% reduction in risk of death (OS HR 0.65)
RAPPORT translational analysis: T cell trafficking governs response to SABR plus anti-PD-1 in kidney cancer — CD8+ Texprog predicted PFS (HR 3.1, p=0.03)
Germline CDK12 variants identified as a rare hereditary driver of aggressive prostate cancer — Germline CDK12 truncating variants found in 5 of 4,535 patients (0.1%) with metastatic prostate cancer
Phase III adjuvant pelvic IMRT after cystectomy improves locoregional control in high-risk MIBC (BART) — 2-yr LRFS 87.1% vs 76.0%, HR 0.43, p=0.04; DFS 71.6% vs 58.7%, HR 0.62; OS 70.4% vs 57.4%, HR 0.78
OMNIVORE follow-up: response-adapted nivolumab lets some RCC patients stop treatment durably — Half of early responders were off therapy after 1 year and 75% of early responders were alive after 59.4-month follow-up; 83% vs 63% 3-year OS between arms

Full details below ↓

📄 What's Being Published

Manuscripts:

Single, early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial. — Ito Akihiro et al., Lancet Oncol

In this phase 3 trial, 3-year relapse-free survival was 60.0% (95% CI 51.7–67.3) in the pirarubicin group and 47.0% (95% CI 38.7–54.9) in the observation group (HR 0.67 [90.96% CI 0.50–0.88]; p=0.0066). The most common grade 3–4 adverse event was haematuria, occurring in four (3%) patients in the pirarubicin group and none in the observation group.

Clinical bottom line: A single postoperative intravesical pirarubicin instillation after radical nephroureterectomy reduces bladder recurrence with manageable toxicity and should be considered standard for upper tract urothelial carcinoma.

Read full article →

MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-invasive Bladder Cancer: An Analysis of Inter-radiologist Variability and Diagnostic Accuracy in three Prospective Clinical Trials. — Greidanus Joyce et al., Eur Urol Oncol

Semi-automatic volumetric analysis showed high reproducibility and accuracy quantitatively (ICC = 0.93, 95% CI: 0.83–0.95, AUC = 0.8–0.98), while visual assessment demonstrated high inter-radiologist agreement among qualitative methods (α = 0.79, 95% CI: 0.68–0.87). The analysis drew on data from three prospective clinical trials evaluating neoadjuvant immunotherapy in muscle-invasive bladder cancer.

Clinical bottom line: Semi-automatic volumetric mpMRI is a reproducible, accurate tool for assessing local response to neoadjuvant immunotherapy in MIBC but requires prospective validation before guiding bladder-sparing decisions.

Read full article →

Shallow Whole-Genome Sequencing to Assess Genomic Instability and Predict Treatment Response in Metastatic Castration-Resistant Prostate Cancer. — Slootbeek Peter H J et al., JCO Precis Oncol

Samples with pathogenic variants in BRCA1, BRCA2, or PALB2 (BRCA complex) had a significantly higher median genomic instability score (GIS) (38 v 26, P < .0005). Adding GIS to BRCA-complex status improved PSA response prediction in logistic models for PARP inhibitors (AUC 0.849 v 0.781, P = .0308).

Clinical bottom line: Genomic instability scoring by cost-effective shallow whole-genome sequencing adds predictive value beyond BRCA-complex status for PARP inhibitor response in mCRPC.

Read full article →

Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making. — Thibault Constance et al., Eur Urol Oncol

Clinically, only FGFR3 alterations currently guide therapy, with erdafitinib approved by the FDA and the European Medicines Agency for FGFR3-altered metastatic disease. Muscle-invasive bladder cancer displays high genomic instability, with recurrent mutations in TP53, RB1, and chromatin modifiers, as well as frequent alterations in the RTK/RAS/PI3K pathway.

Clinical bottom line: Molecular profiling has clarified bladder cancer biology, but only FGFR3 currently guides therapy and clinical implementation of other biomarkers remains limited pending prospective trials.

Read full article →

Adjuvant penpulimab in very-high risk clear cell renal cell carcinoma: a prospective, non-randomized, controlled phase II trial with integrated plasma multi-omics analyses. — Wang Yaohui et al., J Immunother Cancer

Adjuvant penpulimab was associated with improved disease-free survival compared with surveillance (HR 0.37; 95% CI 0.16 to 0.89; p=0.026), with 1-year DFS rates of 94.25% vs 80.46% and 2-year DFS rates of 88.68% vs 75.38% favoring the penpulimab group. Overall survival data remained immature at the time of analysis.

Clinical bottom line: Adjuvant penpulimab was associated with improved disease-free survival and manageable toxicity in very-high risk ccRCC, though the non-randomized design and immature OS temper conclusions.

Read full article →

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program. — Domènech Heura et al., NPJ Precis Oncol

HRD was more frequent in high-grade ovarian cancer (52%) than in metastatic breast cancer (12%) or prostate cancer (20%). Longitudinal ctDNA sequencing revealed BRCA1/BRCA2 reversion mutations in >30% of post-PARPi metastatic breast cancer samples, which were associated with poor response to subsequent platinum therapy.

Clinical bottom line: Complementary HRD biomarkers in tissue and liquid biopsy, including RAD51 testing and genomic instability scoring, detect PARP inhibitor sensitivity missed by mutation testing and can monitor reversion-driven resistance.

Read full article →

🗣️ What People Were Discussing This Week

How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).

FDA approves perioperative enfortumab vedotin plus pembrolizumab for all cystectomy-eligible MIBC (KEYNOTE-B15/EV-304)

KEYNOTE-B15/EV-304 demonstrated a 47% reduction in the risk of recurrence, progression, or death (EFS HR 0.53) and a 35% reduction in the risk of death (OS HR 0.65), with 2-year EFS of 79.4% vs 66.2% and 2-year OS of 86.9% vs 81.3%; pathological complete response was 55.8% vs 32.5%. The FDA approval of perioperative enfortumab vedotin plus pembrolizumab across all cystectomy-eligible MIBC patients makes platinum eligibility somewhat redundant, with oncologists debating whether a platinum-free perioperative regimen can cure some patients without surgery and how much systemic therapy is truly needed.

Discussed by: @tompowles1, @DrChoueiri, @neerajaiims, @OncBrothers, @nataliagandur, @TischCancer

→ View representative tweet

RAPPORT translational analysis: T cell trafficking governs response to SABR plus anti-PD-1 in kidney cancer

Translational data from the RAPPORT analysis showed that response to SABR plus anti-PD-1 in kidney cancer was governed by trafficking and maintenance of pre-existing T cell clones, not new clonal expansion, with CD8+ Texprog predicting progression-free survival (HR 3.1, p=0.03). The central question for clinicians is whether pre-existing progenitor-exhausted T cell infiltrate can serve as a reliable predictive biomarker for combining radiation with immunotherapy in RCC.

Discussed by: @_ShankarSiva, @OncoAlert

→ View representative tweet

Germline CDK12 variants identified as a rare hereditary driver of aggressive prostate cancer

Rare germline CDK12 truncating variants were identified in 5 of 4,535 patients (0.1%) with metastatic prostate cancer, challenging the prior assumption that CDK12 alterations are exclusively somatic; among 4,534 men with aggressive prostate cancer, these 5 carriers developed cancer young with strong family histories. The clinical debate centers on whether germline CDK12 should be added to hereditary prostate cancer testing panels given its association with lethal disease and familial segregation.

Discussed by: @DrMHofman, @ElizSMcKenna

→ View representative tweet

Phase III adjuvant pelvic IMRT after cystectomy improves locoregional control in high-risk MIBC (BART)

The BART phase III trial reported 2-year locoregional recurrence-free survival of 87.1% vs 76.0% (HR 0.43, p=0.04) with adjuvant pelvic IMRT, alongside DFS of 71.6% vs 58.7% (HR 0.62) and OS of 70.4% vs 57.4% (HR 0.78); survival endpoints trended consistently in favor of radiotherapy but were not statistically significant in a 153-patient trial. Specialists are weighing whether the locoregional control benefit translates into survival and how adjuvant IMRT fits alongside adjuvant immunotherapy or perioperative enfortumab vedotin plus pembrolizumab in the current treatment landscape.

Discussed by: @katy_beckermann, @drnurullahilhan

→ View representative tweet

OMNIVORE follow-up: response-adapted nivolumab lets some RCC patients stop treatment durably

Extended follow-up of OMNIVORE showed that 50% of early responders were off therapy after 1 year, 75% of early responders were alive after 59.4-month follow-up, and 3-year overall survival was 83% vs 63% between arms. The central question for oncologists is whether early response to induction nivolumab can reliably identify RCC patients who can safely discontinue immunotherapy.

Discussed by: @CancerNetwrk, @BraunMDPhD

→ View representative tweet

FDA approves durvalumab plus BCG for high-risk NMIBC (POTOMAC)

The FDA approved durvalumab plus BCG for high-risk non-muscle-invasive bladder cancer on the basis of the POTOMAC trial, which showed improved disease-free survival versus BCG alone. Clinicians are now considering how the addition of checkpoint inhibition to BCG will reshape first-line management of high-risk NMIBC.

Discussed by: @ClinOncNews, @UroDocAsh

→ View representative tweet

🔥 Top Ranked Tweets

OncoAlert @OncoAlert

RT @nataliagandur: 🚨 Can we improve on the current adjuvant standard in high-risk ccRCC?
@OncoAlert @NEJM @DrChoueiri @OpenMedicineHQ @OpenMedInsights
The phase 3 LITESPARK-022 trial suggests the answer may be yes.

Adding belzutifan to pembrolizumab after surgery improved disease-free survival compared with pembrolizumab alone in patients with resected clear-cell #KidneyCancer—at the expense of increased grade ≥3 adverse events.

⚖️ Better efficacy, but with greater toxicity. The challenge now is identifying which patients are most likely to benefit from treatment intensification.

🎥 Watch the NEJM Quick Take:
https://t.co/HrZT5MCpwm
#RCC #GUOncology #AdjuvantTherapy #Immunotherapy #HIF2α

🔖 1 ❤️ 15 🔁 8 👁 2,229